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Lymphocytes strongly contribute to the pathology of
multiple sclerosis (MS). Thereby, frequently activated or
reactivated autoreactive lymphocytes differentiate into
effector cells that enter the central nervous system (CNS)
causing tissue inflammation and damage. In order to
reach the CNS, migratory signals allowing the entry into
the circulatory system are vital. Sphingosine-1-phosphate
(S1P) is a key mediator of lymphocyte egress that binds
to five S1P receptors (S1P1-5). The immunomodulatory
drug fingolimod (FTY720, Gilenya) directly targets S1P
receptors and inhibits lymphocyte egress, whereas the
exact effector function of interferon-b (IFN-b) in MS
therapy remains elusive. However, IFN-b is known to
induce CD69 expression, which by direct interaction,
downmodulates S1P1 surface expression preventing lym-
phocyte egress. Since the block of lymphocyte egress is
not complete, we analyzed subset composition and
migratory responsiveness towards S1P of the lympho-
cytes remaining in the circulation of MS patients treated
with fingolimod or IFN-b. Here we show that fingolimod
treatment increased the responsiveness of the remaining
T-lymphocytes towards S1P and that B cell migration of
IFN-b treated patients changed from weak to normal.
We found changes in the subset composition and abso-
lute numbers in both treatment groups. While fingoli-
mod reduced the number of almost all analyzed subsets
in the circulation IFN-b specifically reduced the numbers
of marginal zone and memory B cells.
In conclusion, we think that by reducing “memory” type
lymphocytes in the circulation fingolimod and IFN-b
impair reactivation of autoreactive cells. In addition, treat-
ment might inhibit the egress of newly formed effector
cells and selects for stronger S1P responsive cells. Taken
together these effects contribute to an overall beneficial
outcome.
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